OJEMDA™ (tovorafenib), FDA Approved for Pediatric Low-Grade Glioma, Available at Biologics by McKesson

April 26, 2024

CARY, N.C., April 26, 2024 —, an independent specialty pharmacy specializing in oncology and rare disease, was selected by Day One Biopharmaceuticals, as a limited network specialty pharmacy for OJEMDATM (tovorafenib) for the treatment of pediatric low-grade glioma (pLGG).

OJEMDA, granted Rare Pediatric Disease Designation and approved by the U.S. Food and Drug Administration (FDA) on April 23, 2024, is an oral, brain-penetrant, highly selective type II RAF kinase inhibitor for the treatment of pLGG. Although considered a slow-growing tumor, pLGGs press on surrounding parts of the brain, which affects its function.

“OJEMDA provides a new therapy option for patients impacted by pLGG, which has the potential to make a lasting impact on them,” said George Paschal, senior director of Business Development for Biologics by McKesson. “Biologics is honored to be chosen as a specialty pharmacy provider by Day One Biopharmaceuticals to offer this new therapy for patients with pLGG.”

Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, Biologics includes teams of pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.

For more information about the symptoms, diagnosis, and treatment of pLGG, please click . For more information about OJEMDA, including full prescribing information, please click .

OJEMDATM is a trademark of Day One Biopharmaceuticals.

About Biologics by McKesson

is an independent specialty pharmacy with more than 30 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As a business within 海角社区, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers, and biopharma, so together, they can deliver better care and outcomes for every patient.

About McKesson Oncology and Specialty Solutions

It’s an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care.

  • McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through the joint venture between US Oncology Research and .
  • and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers.
  • ®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care.
  • As one of the largest distributors of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them.
  • And through , , and GPO services, our work continues to help patients access, afford, and adhere to their medicines.

PR Contact

Claire Crye
Public Relations
281-825-9927
Claire.Crye@McKesson.com